TwoStep Therapeutics
San Carlos, US · Founded 2023 · Delaware corporation · 12 employees on LinkedIn · 4 known investors
TwoStep Therapeutics is a Stanford spinout developing targeted cancer therapies, including peptide-based drug conjugates and radioligand programs built on a tumor-targeting peptide platform. The company is advancing a preclinical pipeline toward a first clinical trial planned for the second half of 2026.
Founders & leadership
TwoStep Therapeutics was founded in 2023 by Caitlyn Miller, Jennifer Cochran, Carolyn Bertozzi, and Ronald Levy.
CM
Caitlyn MillerCEO & Co-Founder
JC
Jennifer CochranCo-Founder
CB
Carolyn BertozziCo-Founder
RL
Ronald LevyCo-Founder
Board
OA
JP
John PrufetainBoard directorChief Executive Officer and Managing Partner at Medical Excellence Capital
MP
Matias Porras PaniaguaBoard director
Investors · 4
Reported raises · per SEC filings
Form D private placements$27.6M disclosed across 2 rounds · 2024–2026
▶$21.1MraisedJan 2026 · 8 investors · OtherRule 506(b)
▶$21.1MraisedJan 2026 · 8 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Matias Porras PaniaguaDirector
- Caitlyn MillerExecutive Officer, Director, Promoter
- Omri Amirav-DroryDirector
- John PrufetaDirector
- Offering amount
- $62.2M
- Amount sold
- $21.1M
- First sale
- Jan 2026
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
▶$6.5MraisedMar 2024 · 6 investors · OtherRule 506(b)
▶$6.5MraisedMar 2024 · 6 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Caitlyn MillerExecutive Officer, Director, Promoter
- Omri Amirav-DroryDirector
- Offering amount
- $6.5M
- Amount sold
- $6.5M
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware, 2023
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 8
by search overlap
Solu6 shared keywordsSolu Therapeutics is a clinical-stage biotech developing a class of antibody therapeutics that link bifunctional small molecules to proprietary effector antibodies (its CyTAC and TicTAC platforms) to reach cell surface targets like GPCRs and ion channels. Its pipeline targets oncology, immunology and inflammation, and pain, with a lead program in Phase 1 trials for chronic myelomonocytic leukemia.
Bioworld6 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Transcode Therapeutics6 shared keywordsTransCode Therapeutics is a clinical-stage company developing immuno-oncology and RNA-based therapeutics for high-risk and advanced cancers. Its lead candidate, TTX-MC138, targets microRNA-10b to treat patients with metastatic cancer and is in Phase 2a clinical trials.
Stoke Therapeutics6 shared keywords
A2 Biotherapeutics6 shared keywordsA2 Bio develops precision CAR T-cell therapies using its Tmod cell engineering platform for both autologous and allogeneic applications. The company targets cancer and other serious diseases and advances its therapies through clinical trials.
Nested Therapeutics5 shared keywordsNested Therapeutics is a precision oncology company developing small-molecule cancer therapeutics by identifying overlooked driver mutations and novel binding pockets through a drug discovery platform combining genomics, computational biophysics, machine learning, and chemical biology. Its lead program, NST-628, is a brain-penetrant pan-RAF/MEK molecular glue in Phase 1 trials for MAPK-driven solid tumors, alongside a mutation-selective p53-pathway program.
Applied Therapeutics5 shared keywordsApplied Therapeutics is a biopharmaceutical company developing novel drugs for rare diseases with high unmet medical need. Its Aldose Reductase Inhibitor franchise is in development across disease areas including Galactosemia and SORD Deficiency.
Biotechtv5 shared keywordsBiotechTV is a media outlet producing video shows, event coverage, and news focused on the biotech and healthcare sectors, including topics like venture funding, oncology conferences, and drug development. Its programming covers industry events, CEO interviews, science spotlights, and AI news for a biotech and life sciences audience.
Companies competing with TwoStep Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does TwoStep Therapeutics do?
- TwoStep Therapeutics is a Stanford spinout developing targeted cancer therapies, including peptide-based drug conjugates and radioligand programs built on a tumor-targeting peptide platform. The company is advancing a preclinical pipeline toward a first clinical trial planned for the second half of 2026.
- Who founded TwoStep Therapeutics?
- TwoStep Therapeutics was founded by Caitlyn Miller, Jennifer Cochran, Carolyn Bertozzi, Ronald Levy in 2023.
- Who are TwoStep Therapeutics's investors?
- TwoStep Therapeutics's investors include 2048 Ventures, Fifty Years, Medical Excellence Capital, NFX.
- How much funding has TwoStep Therapeutics raised?
- TwoStep Therapeutics has disclosed $27.6M raised across 2 rounds.
- Where is TwoStep Therapeutics headquartered?
- TwoStep Therapeutics is headquartered in San Carlos, US.